Dexdor

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification [1] issued on	Commission Decision Issued [2] / amended on	Product Information affected [3]	Summary
II/0035	Update of section 4.4 of the SmPC and PL section 2 in order to add a new warning on increased mortality in ICU patients ≤65 years old, based on results from Study SPICE III (randomised controlled trial) and following the assessment of the post-authorisation measure LEG 16.4. In addition, the MAH took the	19/05/2022	08/07/2022	SmPC and PL	For more information, please refer to the Summary of Product Characteristics and the Package Leaflet.

[1] Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.
[2] A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.
[3] SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

	opportunity to update the list of local representatives in the Package Leaflet. The RMP version 9.1, a DHPC and communication plan have also been agreed. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data				
PSUSA/998/202103	Periodic Safety Update EU Single assessment - dexmedetomidine	14/10/2021	16/12/2021	SmPC and PL	Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/998/202103.
IA/0033	B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)	16/10/2020	n/a		
PSUSA/998/202003	Periodic Safety Update EU Single assessment - dexmedetomidine	01/10/2020	n/a		PRAC Recommendation - maintenance
N/0031	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	07/05/2020	16/12/2021	PL	
PSUSA/998/201903	Periodic Safety Update EU Single assessment - dexmedetomidine	14/11/2019	13/01/2020	SmPC and PL	Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/998/201903.
PSUSA/998/201803	Periodic Safety Update EU Single assessment - dexmedetomidine	15/11/2018	18/01/2019	SmPC and PL	Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/998/201803.

N/0029	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	10/10/2018	18/01/2019	PL	
IA/0028	B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place	07/09/2018	n/a		
II/0026	C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one	28/06/2018	02/08/2018	SmPC and PL	Please refer to the Assessment Report Dexdor-H-C-2268-II-0026-Assessment Report-Variation
IAIN/0025	C.I.11.a - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of wording agreed by the competent authority	08/12/2017	n/a		
PSUSA/998/201703	Periodic Safety Update EU Single assessment - dexmedetomidine	12/10/2017	08/12/2017	SmPC and PL	Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/998/201703.
IA/0024	B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier	03/08/2017	n/a		
IA/0022	B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information	16/12/2016	n/a		

PSUSA/998/201603	Periodic Safety Update EU Single assessment - dexmedetomidine	29/09/2016	n/a		PRAC Recommendation - maintenance
IA/0021	B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information	15/09/2016	n/a		
R/0019	Renewal of the marketing authorisation.	01/04/2016	26/05/2016	SmPC, Labelling and PL	Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Dexdor in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.
IB/0017/G	This was an application for a group of variations. B.I.b.2.c - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure for a reagent, which does not have a significant effect on the overall quality of the AS B.I.b.2.c - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure for a reagent, which does not have a significant effect on the overall quality of the AS B.I.b.2.c - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure for a reagent, which does not have a significant effect on the overall quality of the AS B.I.b.2.c - Change in test procedure for AS or	05/01/2016	n/a		

	starting material/reagent/intermediate - Other changes to a test procedure for a reagent, which does not have a significant effect on the overall quality of the AS B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation				
IA/0018	B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier	02/12/2015	n/a		
II/0014	C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority	19/11/2015	n/a		
IA/0015/G	This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of	12/11/2015	n/a		

	manufacturing sites				
PSUSA/998/201503	Periodic Safety Update EU Single assessment - dexmedetomidine	08/10/2015	n/a		PRAC Recommendation - maintenance
II/0011/G	This was an application for a group of variations. B.II.f.1.d - Stability of FP - Change in storage conditions of the finished product or the diluted/reconstituted product C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	25/06/2015	03/11/2015	SmPC, Annex II, Labelling and PL	
IAIN/0012	C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location	18/03/2015	n/a		
PSUSA/998/201409	Periodic Safety Update EU Single assessment - dexmedetomidine	12/03/2015	n/a		PRAC Recommendation - maintenance
II/0009	Update of sections 4.4 and 4.8 of the SmPC in order to add a warning and update the safety information on respiratory depression and apnoea. Update of section 4.5 of the SmPC to add information on enhancement of effects, including sedative, anaesthetic and cardiorespiratory effects. Update of section 5.1 to introduce further clarification on respiratory depressive effects. The Package Leaflet is updated accordingly. In addition, the MAH took the	20/11/2014	03/11/2015	SmPC, Annex II and PL	Data submitted by the MAH indicate that there is sufficient evidence to suggest a possible causal association between respiratory depression/ apnoea and dexmedetomidine. Co-administration of dexmedetomidine with anaesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. Based on this data the Product information for Dexdor has been updated accordingly.

	opportunity to bring the PI in line with the latest QRD template version 9.0, and has made a linguistic correction in EN Annex: the word sulphate in SmPC section 6.6 and Patient Information Leaflet section 6 has been changed to word sulfate. The MAH took also the opportunity to update the local representative details for Greece and Latvia. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation				
PSUV/0008	Periodic Safety Update	09/10/2014	n/a		PRAC Recommendation - maintenance
PSUV/0007	Periodic Safety Update	10/04/2014	n/a		PRAC Recommendation - maintenance
N/0006	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	04/12/2013	18/12/2013	PL	
IA/0005/G	This was an application for a group of variations. B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure	15/11/2013	n/a		
II/0004/G	This was an application for a group of variations. To add a new pack size: 5 x 2 ml glass vials.	21/03/2013	18/12/2013	SmPC, Labelling and PL	

	To change the name of rubber stopper's supplier. To change the name of the glass vial's supplier. B.II.e.5.c - Change in pack size of the finished product - Change in the fill weight/fill volume of sterile multidose (or single-dose, partial use) parenteral medicinal products, and biological/immunological multidose parenteral medicinal products B.II.e.7.z. - Change in supplier of packaging components or devices (when mentioned in the dossier) - Other variation B.II.e.7.z. - Change in supplier of packaging components or devices (when mentioned in the dossier) - Other variation				
II/0003	Update of sections 4.2, 4.8, 5.1 and 5.2 of the SmPC to revise the paediatric information based on the results of new paediatric studies submitted in accordance with article 46 of the Paediatric Regulation. Details of the local representative in Italy were updated. Linguistic changes are made in the following countries: Greece, France, Italy, Czech Republic. Annex II was also updated in accordance with the latest template. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre-clinical, clinical or pharmacovigilance data	13/12/2012	18/12/2013	SmPC, Annex II and PL	Please refer to the Assessment Report 'Dexdor-H-C-2268-II-0003-Assessment Report-Variation.
N/0002	The Marketing Authorisation Holder (MAH) took the	09/08/2012	18/12/2013	PL	

	opportunity to update details of local representatives in Annex IIIB. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)				
N/0001	The Marketing Authorisation Holder (MAH) took the opportunity to correct local representatives in Annex IIIB and some minor errors in the Annexes IIIA and IIIB of all other languages following QRD recommendations. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	03/02/2012	18/12/2013	Labelling and PL	